

R₄ is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanoyl of 2 to 7 carbon atoms;

B' c
c

R₅ and R₆ are independently hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, ^{or} trifluoromethyl, ~~or, when taken together, methylene dioxy;~~

R₇ is hydrogen or alkyl of 1 to 6 carbon atoms; and

n is one of the integers 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof.

Amend the claims as follows:

Claims 2, 4-13 and 15-33, line 1 of each, delete "1" and insert -- 37 -- .

Cancel Claims 1 and 14.

Remarks

Reconsideration of the subject application is requested in view of the preceding amendments and the following remarks.

Applicants affirm their election of the invention of Group I (Claims 1-33) as set forth in the restriction requirement presented in the outstanding Official Action. Applicants retain their right to further prosecution of the inventions of Groups II-IV in one or more continuing applications as provided by 35 USC 121.

Claims 1-33 stand rejected under 35 USC 101 on grounds of double patenting over the claims of U.S. S.N. 486,594, the parent application from which this continuation-in-part application arose. Serial No. 486,594 was expressly abandoned on November 5, 1984. Applicants regret the error in permitting this parent application to remain viable after filing the present application. However, this rejection is no longer applicable.

Claims 1-3 stand rejected under 35 USC 112, first and second paragraphs for failing to teach the preparation of the compound wherein R₅ and/or R₆ is cyano